Abstract
Introduction: Nilotinib is a BCS class-IV poorly water-soluble kinase inhibitor drug, that was used for this study to prepare the polymeric nanoparticles by nanoprecipitation technique using Eudragit RL-100 and RS-100 as polymers, Killophore P-188 as a surfactant, and PEG 400 used as a non-volatile, and nontoxic solvent for the improvement of the drug solubility and dissolution rate.
Methods: The initial process and formulation variables are screened out based on the selected critical quality attributes such as drug release (%), particle size (nm), zeta potential (mV), and polydispersity index. The FT-IR and DSC studies reveal that the drug has no compatibility between the selected drug and the polymers and does not show any additional drug peaks after physical mixing and formulations. The prepared nanoparticles were further characterized to evaluate the particle size (nm), polydispersity index (PDI), zeta potential (mV), entrapment efficiency (%), and in-vitro drug release (%). From the in vitro drug release study, Eudragit RL-100 and Killophore P-188-based formulations showed optimum drug entrapment efficiency with improved drug solubility and dissolution rate in PEG 400 compared to Eudragit RS-100-based formulations. The accelerated stability data for the optimized formulation batch (F6) before and after storage conditions at 40±2 0C and 75±5% RH indicates that the optimized formulation (F6) is more stable for up to 6 months without changes in drug entrapment efficiency and in vitro dissolution rate. Dissolution kinetic data and diffusion exponent values suggested that optimized formulation followed the Higuchi model with a non-Fickian transport mechanism.
Results: According to the results, the preparation method proposed in this study is the most suitable for generating polymeric nanoparticles of nilotinib for improved drug solubility and dissolution rate.
Conclusion: The nilotinib-based polymeric nano-formulation proved a potential alternative for better drug release with an enhanced solubility rate.
Graphical Abstract
[1]
Weisberg E, Manley P, Mestan J, Cowan-Jacob S, Ray A, Griffin JD. AMN107 (nilotinib): A novel and selective inhibitor of BCR-ABL. Br J Cancer 2006; 94(12): 1765-9.
[http://dx.doi.org/10.1038/sj.bjc.6603170] [PMID: 16721371]
[http://dx.doi.org/10.1038/sj.bjc.6603170] [PMID: 16721371]
[2]
Elmowafy M, Shalaby K, Elkomy MH, et al. Polymeric nanoparticles for delivery of natural bioactive agents: Recent Advances and Challenges. Polymers 2023; 15(5): 1123.
[http://dx.doi.org/10.3390/polym15051123] [PMID: 36904364]
[http://dx.doi.org/10.3390/polym15051123] [PMID: 36904364]
[3]
Taurin S, Archibald M, Pritchard T, Nehoff H, Rosengren RJ, Greish K. A combination of sorafenib and nilotinib reduces the growth of castrate-resistant prostate cancer. Int J Nanomed 2016; 11: 179-200.
[http://dx.doi.org/10.2147/IJN.S97286] [PMID: 26811677]
[http://dx.doi.org/10.2147/IJN.S97286] [PMID: 26811677]
[4]
Cortese B, D’Amone S, Palama IE. Wool-Like Hollow Polymeric nanoparticles for CML chemo-combinatorial therapy. Pharmaceutics 2018; 10(2): 52.
[http://dx.doi.org/10.3390/pharmaceutics10020052] [PMID: 29670043]
[http://dx.doi.org/10.3390/pharmaceutics10020052] [PMID: 29670043]
[5]
Ostendorf BN, le Coutre P, Kim TD, Quintás-Cardama A. Nilotinib. Recent Results Cancer Res 2014; 201: 67-80.
[http://dx.doi.org/10.1007/978-3-642-54490-3_3] [PMID: 24756785]
[http://dx.doi.org/10.1007/978-3-642-54490-3_3] [PMID: 24756785]
[6]
Sacha T, Saglio G. Nilotinib in the treatment of chronic myeloid leukemia. Future Oncol 2019; 15(9): 953-65.
[http://dx.doi.org/10.2217/fon-2018-0468] [PMID: 30547682]
[http://dx.doi.org/10.2217/fon-2018-0468] [PMID: 30547682]
[7]
Bloom AN, Tian H, Schoen C, Winograd N. Label-free visualization of nilotinib-functionalized gold nanoparticles within single mammalian cells by C60- SIMS imaging. Anal Bioanal Chem 2017; 409(12): 3067-76.
[http://dx.doi.org/10.1007/s00216-017-0262-5] [PMID: 28283715]
[http://dx.doi.org/10.1007/s00216-017-0262-5] [PMID: 28283715]
[8]
Yamauchi T, Ueda T. (Nilotinib as a second-line treatment for chronic myeloid leukemia). Cancer Sci Ryoho 2011; 38(6): 911-5.
[PMID: 21677481]
[PMID: 21677481]
[9]
Kamaly N, Yameen B, Wu J, Farokhzad OC. Degradable controlled-release polymers and polymeric nanoparticles: Mechanisms of controlling drug release. Chem Rev 2016; 116(4): 2602-63.
[http://dx.doi.org/10.1021/acs.chemrev.5b00346] [PMID: 26854975]
[http://dx.doi.org/10.1021/acs.chemrev.5b00346] [PMID: 26854975]
[10]
Bayomi MA. Geometric approach for zero-order release of drugs dispersed in an inert matrix. Pharm Res 1994; 11(6): 914-6.
[http://dx.doi.org/10.1023/A:1018902513411] [PMID: 7937535]
[http://dx.doi.org/10.1023/A:1018902513411] [PMID: 7937535]
[11]
Date AA, Jain A, Khachane P, Nagarsenker MS. Organic solvent-free approach to single step fabrication of eudragit nanoparticles using labrasol. Pharmazie 2010; 65(10): 733-6.
[PMID: 21105574]
[PMID: 21105574]
[12]
Xia D, Quan P, Piao H, et al. Preparation of stable nitrendipine nanosuspensions using the precipitation-ultrasonication method for enhancement of dissolution and oral bioavailability. Eur J Pharm Sci 2010; 40(4): 325-34.
[http://dx.doi.org/10.1016/j.ejps.2010.04.006] [PMID: 20417274]
[http://dx.doi.org/10.1016/j.ejps.2010.04.006] [PMID: 20417274]
[13]
Zheng Y, Yang W, Wang C, et al. Nanoparticles based on the complex of chitosan and polyaspartic acid sodium salt: Preparation, characterization and the use for 5-fluorouracil delivery. Eur J Pharm Biopharm 2007; 67(3): 621-31.
[http://dx.doi.org/10.1016/j.ejpb.2007.04.007] [PMID: 17533123]
[http://dx.doi.org/10.1016/j.ejpb.2007.04.007] [PMID: 17533123]
[14]
Lee MK, Lim SJ, Kim CK. Preparation, characterization and in vitro cytotoxicity of paclitaxel-loaded sterically stabilized solid lipid nanoparticles. Biomaterials 2007; 28(12): 2137-46.
[http://dx.doi.org/10.1016/j.biomaterials.2007.01.014] [PMID: 17257668]
[http://dx.doi.org/10.1016/j.biomaterials.2007.01.014] [PMID: 17257668]
[15]
Chauhan H, Mohapatra S, Munt DJ, Chandratre S, Dash A. Physical-chemical characterization and formulation considerations for solid lipid nanoparticles. AAPS PharmSciTech 2016; 17(3): 640-51.
[http://dx.doi.org/10.1208/s12249-015-0394-x] [PMID: 26292931]
[http://dx.doi.org/10.1208/s12249-015-0394-x] [PMID: 26292931]
[16]
Westesen K, Bunjes H, Koch MHJ. Physicochemical characterization of lipid nanoparticles and evaluation of their drug loading capacity and sustained release potential. J Control Release 1997; 48(2-3): 223-36.
[http://dx.doi.org/10.1016/S0168-3659(97)00046-1]
[http://dx.doi.org/10.1016/S0168-3659(97)00046-1]
[17]
Beck-Broichsitter M, Schmehl T, Gessler T, Seeger W, Kissel T. Development of a biodegradable nanoparticle platform for sildenafil: Formulation optimization by factorial design analysis combined with application of charge-modified branched polyesters. J Control Release 2012; 157(3): 469-77.
[http://dx.doi.org/10.1016/j.jconrel.2011.09.058] [PMID: 21930166]
[http://dx.doi.org/10.1016/j.jconrel.2011.09.058] [PMID: 21930166]
[18]
Quintanar-Guerrero D, Fessi H, Allémann E, Doelker E. Influence of stabilizing agents and preparative variables on the formation of poly(d,l-lactic acid) nanoparticles by an emulsification-diffusion technique. Int J Pharm 1996; 143(2): 133-41.
[http://dx.doi.org/10.1016/S0378-5173(96)04697-2]
[http://dx.doi.org/10.1016/S0378-5173(96)04697-2]
[19]
Kalimuthu S, Yadav AV. Formulation and evaluation of carvedilol loaded eudragit e 100 nanoparticles. Int J Pharm Tech Res 2009; 2: 179-83.
[20]
Pirdadeh-Beiranvand M, Afkhami A, Madrakian T. Magnetic molecularly imprinted electrospun nanofibers for selective extraction of nilotinib from human serum. Anal Bioanal Chem 2020; 412(7): 1629-37.
[http://dx.doi.org/10.1007/s00216-020-02393-2] [PMID: 31965245]
[http://dx.doi.org/10.1007/s00216-020-02393-2] [PMID: 31965245]
